nmdp logo

Donor Selection Strategies to Improve Cell Therapy Outcomes

June 17, 2021


HLA matching in the development of cellular therapies and leading-edge allogeneic therapeutics isn't only about finding the best matches. But also avoiding mismatches that could result in less optimal patient outcomes.

During this on-demand webinar you'll hear from industry experts about research identifying HLA-B mismatches that are most optimal and which cause negative effects. You will also learn about an automated HLA-B leader matching assessment tool that can be used to help avoid mismatching for HLA-B alleles associated with higher risks for future patients.

Understanding donor HLA characteristics and their impact on the final therapy can ultimately improve allogeneic cell therapy outcomes.

Access on-demand webinar

Learning Objectives

  • The science of the HLA-B leader peptide and its functional role in cell therapy outcomes
  • How the HLA-B-leader toolinitially created to support NMDP initiatives and research on optimizing HSCT success using mismatched donors can be used by the cell therapy field in donor source selection
  • The impact these tools and research will have on improving patient outcomes in HSCT and emerging cell and gene therapies


  • Effie Wang Petersdorf, MD, Professor, Clinical Research Division & Madeline Dabney Adams Endowed Chair in AML Research Fred Hutchinson Cancer Research Center
  • Ray Sajulga, Jr., Bioinformatics Scientist NMDP
  • Martin Maiers, MS, Vice President of Innovation NMDP
  • Kim Wadsworth, Senior Immunogenetic Specialist NMDP